Intravitreal Bevacizumab for Foveal Detachment in Idiopathic Perifoveal Telangiectasia

PurposeTo report the use of intravitreal bevacizumab injection for the treatment of foveal detachment in idiopathic perifoveal telangiectasia (IPT).DesignProspective, interventional case series.MethodsThree eyes from two patients with IPT and foveal detachments were treated with a 1.25 mg/0.05 ml intravitreal injection of bevacizumab. The following variables were evaluated: visual acuity and optical coherence tomography (OCT) images.ResultsThe OCT images showed marked reversal of the foveal detachment after the injection, with restoration of foveal depression in all eyes. The vision of all treated eyes improved and remained unchanged up until the last follow-up visit (mean, 24 weeks).ConclusionsA single intravitreal bevacizumab injection provides short-term improvement in visual acuity and foveal detachment associated with IPT. These findings should be followed by further studies to evaluate the long-term effects on retinal structure and function.